For two years, the headlines practically wrote themselves: The blockbuster GLP-1 drugs that melt away pounds might also guard your brain. It was a lovely idea. Then somebody actually tested the theory.
The results are in. And for anyone hoping a weekly injection or daily pill would hold Alzheimer’s at bay, the answer is a letdown.
The hope was real — and reasonable
This wasn’t wishful thinking out of nowhere. Big studies of diabetes patients had found that people taking GLP-1 drugs — the family that includes Ozempic, Wegovy and Rybelsus — seemed to develop dementia less often than people on other diabetes medicines. A smaller trial of a related drug hinted at slower decline.
There’s even a tidy biological story behind it: These drugs can help calm inflammation and steady blood sugar, both of which get blamed for wear and tear on the aging brain.
But those diabetes studies only showed a link, not proof. The only way to know whether the drug truly protects the brain is to give it to people and watch what happens.
Then came the real test
That’s what two large trials, called EVOKE and EVOKE+, set out to do. Together they enrolled 3,808 people ages 55 to 85 who already had mild memory trouble or early Alzheimer’s. Half got a daily pill form of semaglutide — the same drug as in the injectables Ozempic and Wegovy — and half got a dummy pill, for about two years.
The result: The people on the drug declined just about as fast as the people on the placebo. On the trial’s main yardstick for memory and daily function, there was no meaningful difference.
Novo Nordisk, which makes the drug and paid for the studies, announced the miss in late 2025. The full results, led by Alzheimer’s researcher Jeffrey Cummings, landed in the medical journal The Lancet in spring 2026.
Quick thought — most financial “gurus” got rich selling advice, not following it. I’d rather show you what actually works, because I’ve lived it. Sign up for the free Money Talks Newsletter for money advice from someone who takes his own. 10 seconds, no spam.
A silver lining that stayed on paper
There was one flicker of good news, and it’s worth understanding, because you’ll see it spun both ways.
The drug did nudge some of Alzheimer’s underlying markers in the blood and spinal fluid in the right direction, and it tamped down inflammation. But a couple of markers of nerve damage actually rose. And none of it translated into what patients care about: The people on semaglutide didn’t think, remember or function any better than those who got nothing.
The biology twitched. The patients didn’t.
What it means for you
If you take a GLP-1 for diabetes or weight, this changes nothing. Keep taking it for the reasons it was prescribed, and talk with your doctor about the side effects worth watching. What you shouldn’t do is start one, or keep paying for a pricey version, in hopes of protecting your memory. That hope just failed its biggest test.
One honest caveat: This trial gave the drug to people who already had early Alzheimer’s. It didn’t test whether starting it years earlier might prevent the disease in healthy people — and nobody has shown that either. So there’s no version of this where the drug is a proven brain-saver today.
What protects your brain
Here’s the part that never trends, because you can’t sell it in a syringe. A landmark review estimated that up to 45% of dementia cases are tied to risk factors you can actually do something about.
The unglamorous list: Keep your blood pressure, blood sugar and cholesterol in check; move your body most days; don’t smoke; protect your hearing and eyesight; and stay socially and mentally engaged.
Managing diabetes early counts, too — one big study found the first year after diagnosis is a real window.
The lesson under the hype
None of this makes semaglutide a bad drug. It does what it was built to do for blood sugar and weight, and that’s plenty. The trouble starts when a genuine breakthrough in one lane gets sold as a miracle in every other.
I’ve watched that movie for 35 years. The thing that protects your brain isn’t a prescription you pick up. It’s the boring, daily stuff you already know you should be doing. Annoying? Sure. But it’s real, it’s proven, and it’s a lot cheaper than GLP-1s.
Add a Comment